CoChat

Screening for E3-Ubiquitin ligase inhibitors: challenges and opportunities

Open access
Landré, Vivien, Rotblat, Barak, Melino, Sonia, Bernassola, Francesca, Melino, Gerry · 2014 · Oncotarget
Cited by 104

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

// Vivien Landré 1 , Barak Rotblat 1 , Sonia Melino 2 , Francesca Bernassola 2 and Gerry Melino 1,2 1 Medical Research Council, Toxicology Unit, Leicester, UK 2 Biochemistry Laboratory, IDI-IRCCS, c/o Department of Experimental Medicine and Surgery, University of Rome “Tor Vergata”, Rome, Italy Correspondence: Gerry Melino, email: // Keywords : HECT, ITCH, p73, p63, high throughput screening, therapeutics, clomipramine, small molecular inhibitor Received : July 24, 2014 Accepted : September 02, 2014 Published : September 03, 2014 Abstract The ubiquitin proteasome system (UPS) plays a role in the regulation of most cellular pathways, and its deregulation has been implicated in a wide range of human pathologies that include cancer, neurodegenerative and immunological disorders and viral infections. Targeting the UPS by small molecular regulators thus provides an opportunity for the development of therapeutics for the treatment of several diseases. The proteasome inhibitor Bortezomib was approved for treatment of hematologic malignancies by the FDA in 2003, becoming the first drug targeting the ubiquitin proteasome system in the clinic. Development of drugs targeting specific components of the ubiquitin proteasome system, however, has lagged behind, mainly due to the complexity of the ubiquitination reaction and its outcomes. However, significant advances have been made in recent years in understanding the molecular nature of the ubiquitination system and the vast variety of cellular signals that it produces. Additionally, improvement of screening methods, both in vitro and in silico, have led to the discovery of a number of compounds targeting components of the ubiquitin proteasome system, and some of these have now entered clinical trials. Here, we discuss the current state of drug discovery targeting E3 ligases and the opportunities and challenges that it provides.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.2431

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Cited by

See all 104

Metadata

Authors
Landré, V., Rotblat, B., Melino, S., Bernassola, F., & Melino, G.
Venue
Oncotarget
Published
2014-09-03
Volume
5
Issue
18
Pages
7988-8013
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1794063461
Cited by
104
References
34
FWCI
3.53
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Screening for E3-Ubiquitin ligase inhibitors: challenges and opportunities. https://app.cochat.ai/papers/10.18632/oncotarget.2431
The paper
Landré, V., Rotblat, B., Melino, S., Bernassola, F., & Melino, G. (2014). Screening for E3-Ubiquitin ligase inhibitors: challenges and opportunities. Oncotarget. https://doi.org/10.18632/oncotarget.2431

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.